Event Details

The earnings call is scheduled for Monday, 16th November, 2026 at 11:00 hours (IST). This is a continuation of the intimation dated 05th November, 2026.

Q2 FY27 Financial Performance

  • Revenue from Operations: ₹496.3 crore, up 30.5% YoY (from ₹380.4 crore in Q2 FY26)
  • EBITDA: ₹72.4 crore, up 29.2% YoY (from ₹56.1 crore in Q2 FY26)
  • EBITDA Margin: 14.6% (vs 14.7% in Q2 FY26)
  • Profit After Tax: ₹42.4 crore, up 43.0% YoY (from ₹29.7 crore in Q2 FY26)
  • PAT Margin: 8.5% (vs 7.8% in Q2 FY26)
  • EPS: ₹7.41 (vs ₹5.18 in Q2 FY26)
  • Other Income: ₹2.5 crore (vs ₹4.2 crore in Q2 FY26)
  • Cost of Material Consumed: ₹331.6 crore
  • Employee Cost: ₹45.1 crore
  • Other Expenses: ₹49.7 crore
  • Depreciation: ₹11.8 crore
  • Finance Cost: ₹4.3 crore
  • Tax: ₹13.9 crore

H1 FY27 Financial Performance

  • Revenue from Operations: ₹967.2 crore, up 32.1% YoY (from ₹731.9 crore in H1 FY26)
  • EBITDA: ₹147.5 crore, up 31.0% YoY (from ₹112.6 crore in H1 FY26)
  • EBITDA Margin: 15.3% (vs 15.4% in H1 FY26)
  • Profit After Tax: ₹86.5 crore, up 42.6% YoY (from ₹60.7 crore in H1 FY26)
  • PAT Margin: 8.9% (vs 8.3% in H1 FY26)
  • EPS: ₹15.12 (vs ₹10.60 in H1 FY26)
  • Other Income: ₹4.5 crore (vs ₹8.7 crore in H1 FY26)

Business Segment Performance

CDMO Services & Products (70% of total revenue)

  • Q2 FY27 Revenue: ₹345.2 crore, up 30% YoY
  • H1 FY27 Revenue: ₹673.9 crore, up 31% YoY

Branded Generics

  • Q2 FY27 Revenue: ₹151.1 crore, up 32% YoY
  • H1 FY27 Revenue: ₹293.3 crore, up 35% YoY

Balance Sheet Position (as of September 2026)

Assets

  • Total Assets: ₹1,994.1 crore (vs ₹1,837.8 crore in March 2026)
  • Non-Current Assets: ₹884.6 crore
  • Property, plant and equipment: ₹778.5 crore
  • Right of use assets: ₹43.3 crore
  • Capital work-in-progress: ₹9.3 crore
  • Goodwill: ₹16.7 crore
  • Other intangible assets: ₹1.6 crore
  • Current Assets: ₹1,109.4 crore
  • Inventories: ₹316.9 crore
  • Trade receivables: ₹490.2 crore
  • Cash and cash equivalents: ₹14.9 crore
  • Investments: ₹82.9 crore

Equity & Liabilities

  • Total Equity: ₹1,167.6 crore (vs ₹1,081.5 crore in March 2026)
  • Share Capital: ₹57.2 crore (unchanged)
  • Other Equity: ₹1,110.3 crore
  • Non-Current Liabilities: ₹253.3 crore
  • Borrowings: ₹200.3 crore
  • Current Liabilities: ₹573.2 crore
  • Borrowings: ₹154.1 crore
  • Trade payables: ₹336.7 crore

Cash Flow Highlights (H1 FY27)

  • Cash generated from Operations: ₹42.1 crore
  • Net Cash from Operating Activities: ₹29.7 crore
  • Net Cash from Investing Activities: ₹(64.4) crore
  • Net Cash from Financing Activities: ₹3.1 crore
  • Net increase in Cash and Cash equivalents: ₹11.2 crore

Operational and Strategic Highlights

  • Jammu manufacturing facility completed its first full year and is ramping up well
  • Multiple marquee client audits successfully completed at Jammu facility
  • Received Certificate of GMP Compliance by UK-MHRA for Cephalosporin, Baddi facility
  • Received Certificate of GMP Compliance from PIC/S (SMDC, Ukraine) for Kathua, Jammu facility
  • Jammu facility eligible for Central Government's 'New Central Sector Scheme' benefits including GST-linked incentive totaling to 300% of investment made in eligible plant and machinery available for 10 years, and capital interest subvention of 6% per annum on loan against eligible capex
  • 350+ CDMO customers
  • Products exported to 60+ countries
  • 60+ scientists and engineers in R&D
  • Dedicated R&D facility in Baddi, Himachal Pradesh recognized by DSIR

Historical Financial Performance

FY26 Performance

  • Revenue from Operations: ₹1,630.0 crore
  • EBITDA: ₹250.3 crore (15.4% margin)
  • PAT: ₹143.2 crore (8.8% margin)
  • EPS: ₹25.02

Board of Directors

  • Mr. Manoj Kumar Lohariwala: Chairman and Whole-Time Director
  • Mr. Vinay Lohariwala: Managing Director
  • Mr. Jayant Vasudeo Rao: Whole-Time Director
  • Mr. Archit Aggarwal: Non-Executive Non-Independent Director
  • Mr. Sudhir Kumar Bassi: Non-Executive Independent Director
  • Ms. Priyanka Dixit Sibal: Non-Executive Independent Director
  • Mr. Mahendar Korthiwada: Non-Executive Independent Director
  • Mr. Shirish Gundopant Belapure: Non-Executive Independent Director

Company Background

Innova Captab Limited is a pharmaceutical company with comprehensive business model including CDMO Services and Branded Generics. The company was founded in 2006 with first manufacturing facility in Baddi, Himachal Pradesh. Key milestones include:

  • 2013: Received GMP certification for cephalosporin products from Kenya
  • 2015: Incorporated Univentis Medicare Limited (marketing arm)
  • 2023: Acquisition of Sharon and successful IPO
  • 2025: Commercial operations commenced at Kathua, Jammu facility